Carcinogenicity and DNA adduct formation of 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone and enantiomers of its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol in F-344 rats

Carcinogenesis

Volumn 35, Issue 12, 2014, Pages 2798-2806

  Balbo, Silvia ^a   Johnson, Charles S ^a   Kovi, Ramesh C ^a   James Yi, Sandra A ^a   Gerard O'Sullivan, M ^a   Wang, Mingyao ^a   Le, Chap T ^a   Khariwala, Samir S ^a   Upadhyaya, Pramod ^a   Hecht, Stephen S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 O [4 (3 PYRIDYL) 4 OXOBUT 1 YL]THYMIDINE; 4 (3 PYRIDYL) 4 HYDROXYBUT 1 YL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 6 O METHYLGUANINE; 6 O [4 (3 PYRIDYL) 4 OXOBUT 1 YL]DEOXYGUANOSINE; 7 [4 (3 PYRIDYL) 4 OXOBUT 1 YL]GUANINE; GUANINE DERIVATIVE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTAN-1-OL; 4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; CARCINOGEN; DNA ADDUCT; NITROSAMINE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; ENANTIOMER; FISCHER 344 RAT; LUNG ADENOMA; LUNG CARCINOMA; MALE; NONHUMAN; PANCREAS METASTASIS; PANCREAS TUMOR; PRIORITY JOURNAL; RAT; ADENOCARCINOMA; ADENOMA; ANIMAL; APOPTOSIS; CHEMICALLY INDUCED; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; SECONDARY; STEREOISOMERISM;

ADENOCARCINOMA; ADENOMA; ANIMALS; APOPTOSIS; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; DNA DAMAGE; HUMANS; LUNG NEOPLASMS; MALE; NITROSAMINES; PANCREATIC NEOPLASMS; PYRIDINES; RATS; RATS, INBRED F344; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM;

EID: 84964698306     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu204     Document Type: Article

References (60)

1. Stewart, B.W. et al. (2014) World Cancer Report 2014. IARC, Lyon, FR.
2. World Health Organization. Cancer Fact Sheet N°297. http://www.who.int/mediacentre/factsheets/fs297/en/index.html (15 January 2014, date last accessed).
3. World Health Organization. Tobacco Free Initiative (TFI). http://www.who.int/tobacco/research/cancer/en/(15 January 2014, date last accessed).
4. Shafey, O. et al. (2009) The Tobacco Atlas. 3rd edn. American Cancer Society and World Lung Foundation, Atlanta, GA.
5. Hecht, S.S. (1998) Biochemistry, biology, and carcinogenicity of tobaccospecific N-nitrosamines. Chem. Res. Toxicol., 11, 559-603.
6. Schüller, H.M. et al. (1994) Transplacental carcinogenicity of low doses of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone administered subcutaneously or intratracheally to hamsters. J. Cancer Res. Clin. Oncol., 120, 200-203.
7. Schüller, H.M. et al. (1993) Transplacental induction of pancreas tumors in hamsters by ethanol and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res., 53, 2498-2501.
8. International Agency for Research on Cancer. (2012) Personal habits and indoor combustions. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, v. 100E. IARC, Lyon, FR, pp. 319-331.
9. Xia, Y. et al. (2011) Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in smokers in the United States: NHANES 2007-2008. Biomarkers, 16, 112-119.
10. Roethig, H.J. et al. (2009) Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob. Res., 11, 1216-1225.
11. Vogel, R.I. et al. (2011) The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers. Biomarkers, 16, 491-497.
12. Carmella, S.G. et al. (2013) High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers. Chem. Res. Toxicol., 26, 1209-1217.
13. Church, T.R. et al. (2009) A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol. Biomarkers Prev., 18, 260-266.
14. Yuan, J.M. et al. (2009) Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res., 69, 2990-2995.
15. Yuan, J.M. et al. (2011) Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res., 71, 6749-6757.
16. Finckh, C. et al. (2001) Expression and NNK reducing activities of carbonyl reductase and 11beta-hydroxysteroid dehydrogenase type 1 in human lung. Chem. Biol. Interact., 130-132, 761-773.
17. Breyer-Pfaff, U. et al. (2004) Enantioselectivity of carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat and by enzymes isolated from human liver. Drug Metab. Dispos., 32, 915-922.
18. Upadhyaya, P. et al. (2000) Formation and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers in vitro in mouse, rat and human tissues. Carcinogenesis, 21, 1233-1238.
19. Trushin, N. et al. (2008) The tobacco carcinogen NNK is stereoselectively reduced by human pancreatic microsomes and cytosols. Langenbecks Arch. Surg., 393, 571-579.
20. Yang, Y. et al. (2011) Metabolic study of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone to the enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in vitro in human bronchial epithelial cells using chiral capillary electrophoresis. J. Chromatogr. A, 1218, 6505-6510.
21. Carmella, S.G. et al. (1999) Stereochemistry of metabolites of a tobaccospecific lung carcinogen in smokers' urine. Cancer Res., 59, 3602-3605.
22. Hecht, S.S. et al. (2002) Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. Cancer Res., 62, 129-134.
23. Upadhyaya, P. et al. (1999) Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Carcinogenesis, 20, 1577-1582.
24. Lao, Y. et al. (2007) Formation and accumulation of pyridyloxobutyl DNA adducts in F344 rats chronically treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem. Res. Toxicol., 20, 235-245.
25. Upadhyaya, P. et al. (2008) Quantitation of pyridylhydroxybutyl-DNA adducts in liver and lung of F-344 rats treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem. Res. Toxicol., 21, 1468-1476.
26. Zhang, S. et al. (2009) Analysis of pyridyloxobutyl and pyridylhydroxybutyl DNA adducts in extrahepatic tissues of F344 rats treated chronically with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem. Res. Toxicol., 22, 926-936.
27. Beland, F.A. et al. (1982) Persistence of DNA adducts in rat liver and kidney after multiple doses of the carcinogen N-hydroxy-2-acetylaminofluorene. Cancer Res., 42, 1348-1354.
28. Gupta, R.C. et al. (1988) Analysis of DNA adducts in putative premalignant hepatic nodules and nontarget tissues of rats during 2-acetylaminofluorene carcinogenesis. Cancer Res., 48, 5270-5274.
29. Poirier, M.C. et al. (1984) DNA adduct formation, removal and persistence in rat liver during one month of feeding 2-acetylaminofluorene. Carcinogenesis, 5, 1591-1596.
30. Herron, D.C. et al. (1982) DNA methylation during chronic administration of 1, 2-dimethylhydrazine in a carcinogenic regimen. Carcinogenesis, 3, 857-860.
31. Swenberg, J.A. et al. (1987) The molecular dosimetry of DNA adducts formed by continuous exposure of rats to alkylating hepatocarcinogens. Prog. Exp. Tumor Res., 31, 42-51.
32. Buss, P. et al. (1990) Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1. Carcinogenesis, 11, 2133-2135.
33. Yamashita, K. et al. (1990) DNA adducts formed by 2-amino-3, 8-dimethylimidazo[4, 5-f]quinoxaline in rat liver: dose-response on chronic administration. Jpn. J. Cancer Res., 81, 470-476.
34. Zaidi, N.H. et al. (1993) Tissue and cell specific methylation, repair and synthesis of DNA in the upper gastrointestinal tract of Wistar rats treated with N-methyl-N'-nitro-N-nitrosoguanidine via the drinking water. Carcinogenesis, 14, 1991-2001.
35. Talaska, G. et al. (1996) Chronic, topical exposure to benzo[a]pyrene induces relatively high steady-state levels of DNA adducts in target tissues and alters kinetics of adduct loss. Proc. Natl. Acad. Sci. U. S. A., 93, 7789-7793.
36. 2-ethylidene-dG adducts in mice: implications for alcohol-related carcinogenicity of the oral cavity and esophagus. Biomarkers, 17, 269-274.
37. Zhao, L. et al. (2013) Quantitation of pyridyloxobutyl-DNA adducts in tissues of rats treated chronically with (R)-or (S)-N'-nitrosonornicotine (NNN) in a carcinogenicity study. Chem. Res. Toxicol., 26, 1526-1535.
38. Hecht, S.S. et al. (1997) Absolute configuration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol formed metabolically from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis, 18, 1851-1854.
39. Hecht, S.S. et al. (1980) Metabolism in the F344 rat of 4-(N-methyl-Nnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Cancer Res., 40, 4144-4150.
40. 6-methylguanine, pyridyloxobutyl-, and pyridylhydroxybutyl-DNA adducts in lung and liver of rats treated chronically with the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Drug Metab. Dispos., 37, 1147-1151.
41. Stepanov, I. et al. (2013) Analysis of 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB)-releasing DNA adducts in human exfoliated oral mucosa cells by liquid chromatography-electrospray ionization-tandem mass spectrometry. Chem. Res. Toxicol., 26, 37-45.
42. Wang, M. et al. (2003) Identification of adducts formed by pyridyloxobutylation of deoxyguanosine and DNA by 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone, a chemically activated form of tobacco specific carcinogens. Chem. Res. Toxicol., 16, 616-626.
43. Rivenson, A. et al. (1988) Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res., 48, 6912-6917.
44. National Toxicology Program. (2014) Chemicals Associated with Site-Specific Neoplasia. http://ntp.niehs.nih.gov/?objectid=DA65BAEA-CF6BCDFF-6213E6AE0FD281EB (15 January 2014, date last accessed).
45. 6-Methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis in A/J mouse lung. Cancer Res., 51, 5557-5564.
46. Ronai, Z.A. et al. (1993) G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis, 14, 2419-2422.
47. Murphy, S.E. et al. (1990) Dose-response study of DNA and hemoglobin adduct formation by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344 rats. Cancer Res., 50, 5446-5452.
48. 2-(3-pyridyl)-4-oxobutylthymine, the most persistent bulky adduct produced by the tobacco specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by model DNA polymerases. Chem. Res. Toxicol., 25, 1195-1202.
49. 2-alkylthymidines are potent mutagenic lesions in SOS-induced Escherichia coli. Chem. Res. Toxicol., 24, 1833-1835.
50. 6-[4-oxo-4-(3-pyridyl)butyl]guanine in Escherichia coli and human cells. Chem. Res. Toxicol., 15, 165-169.
51. Delaney, J.C. et al. (2008) Biological properties of single chemical-DNA adducts: a twenty year perspective. Chem. Res. Toxicol., 21, 232-252.
52. Staretz, M.E. et al. (1997) Effects of long term dietary phenethyl isothiocyanate on the microsomal metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in F344 rats. Carcinogenesis, 18, 1715-1722.
53. Staretz, M.E. et al. (1997) Evidence for an important role of DNA pyridyloxobutylation in rat lung carcinogenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: effects of dose and phenethyl isothiocyanate. Cancer Res., 57, 259-266.
54. Wu, H. et al. (2013) Transcriptional suppression of CYP2A13 expression by lipopolysaccharide in cultured human lung cells and the lungs of a CYP2A13-humanized mouse model. Toxicol. Sci., 135, 476-485.
55. Jalas, J.R. et al. (2005) Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem. Res. Toxicol., 18, 95-110.
56. Schlöbe, D. et al. (2008) 4-Hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in lung, lower esophagus and cardia of sudden death victims. Toxicology, 245, 154-161.
57. Foiles, P.G. et al. (1991) Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chem. Res. Toxicol., 4, 364-368.
58. Zimmerman, C.L. et al. (2004) Stereoselective metabolism and tissue retention in rats of the individual enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis, 25, 1237-1242.
59. Murphy, S.E. et al. (1995) Glucuronidation of 4-(hydroxymethylnitrosamino)-1-(3-pyridyl)-1-butanone, a metabolically activated form of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, by phenobarbital-treated rats. Chem. Res. Toxicol., 8, 772-779.
60. Hecht, S.S. (2014) It is time to regulate carcinogenic tobacco-specific nitrosamines in cigarette tobacco. Cancer Prev. Res. (Phila)., 7, 639-647.